Search research articles
Contact Us
Filters
Showing results (71-80 of 450) with videos related to
Page
of 45
Sort By:
Nature Reviews. Drug Discovery
|
December 13, 2005
Finding new tricks for old drugs: an efficient route for public-sector drug discovery
Kerry A O'Connor, Bryan L Roth
Expert Opinion on Therapeutic Targets
|
January 24, 2003
Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development
Bryan L Roth, David A Shapiro
Frontiers in Molecular Neuroscience
|
November 7, 2009
Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors
Charles D Nichols, Bryan L Roth
American Journal of Physiology. Cell Physiology
|
April 17, 2023
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Gavin P Schmitz, Bryan L Roth
The American Journal of Psychiatry
|
May 1, 2023
Psychedelics as Transformative Therapeutics
Bryan L Roth, Ryan H Gumpper
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
March 18, 2023
Psychedelics: preclinical insights provide directions for future research
Ryan H Gumpper, Bryan L Roth
Nature Reviews. Drug Discovery
|
March 18, 2022
The promises and perils of psychedelic pharmacology for psychiatry
Tristan D McClure-Begley, Bryan L Roth
Current Protocols in Neuroscience
|
January 13, 2010
Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution
Ying Pei, Shuyun Dong, Bryan L Roth
Annual Review of Medicine
|
July 28, 2009
The expanded biology of serotonin
Miles Berger, John A Gray, Bryan L Roth
Nature Protocols
|
March 6, 2010
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs
Shuyun Dong, Sarah C Rogan, Bryan L Roth
Page
of 45
Search research articles
Search
Showing results (71-80 of 450) with videos related to
Sort By:
Page
of 45
Nature Reviews. Drug Discovery
|
December 13, 2005
Finding new tricks for old drugs: an efficient route for public-sector drug discovery
Kerry A O'Connor, Bryan L Roth
Expert Opinion on Therapeutic Targets
|
January 24, 2003
Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development
Bryan L Roth, David A Shapiro
Frontiers in Molecular Neuroscience
|
November 7, 2009
Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors
Charles D Nichols, Bryan L Roth
American Journal of Physiology. Cell Physiology
|
April 17, 2023
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Gavin P Schmitz, Bryan L Roth
The American Journal of Psychiatry
|
May 1, 2023
Psychedelics as Transformative Therapeutics
Bryan L Roth, Ryan H Gumpper
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
March 18, 2023
Psychedelics: preclinical insights provide directions for future research
Ryan H Gumpper, Bryan L Roth
Nature Reviews. Drug Discovery
|
March 18, 2022
The promises and perils of psychedelic pharmacology for psychiatry
Tristan D McClure-Begley, Bryan L Roth
Current Protocols in Neuroscience
|
January 13, 2010
Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution
Ying Pei, Shuyun Dong, Bryan L Roth
Annual Review of Medicine
|
July 28, 2009
The expanded biology of serotonin
Miles Berger, John A Gray, Bryan L Roth
Nature Protocols
|
March 6, 2010
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs
Shuyun Dong, Sarah C Rogan, Bryan L Roth
Page
of 45